Alvin C C Ho1,2,3, Shekeeb S Mohammad1,2, Sekhar C Pillai4, Esther Tantsis1,2, Hannah Jones1,5, Reena Ho5, Ming Lim6, Yael Hacohen7, Angela Vincent7, Russell C Dale1,2,8. 1. The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia. 2. Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia. 3. Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong. 4. Department of Neurology, Sydney Children's Hospital and University of New South Wales, Randwick, New South Wales, Australia. 5. Starship Children's Hospital, Auckland, New Zealand. 6. Evelina London Children's Hospital, St. Thomas' Hospital, Children's Neurosciences Centre, London, UK. 7. Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Oxford, UK. 8. Brain and Mind Centre Westmead, University of Sydney, Sydney, New South Wales, Australia.
Abstract
AIM: To determine the validity of the proposed clinical diagnostic criteria for anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in paediatric patients. METHOD: The diagnostic criteria for anti-NMDAR encephalitis proposed by Graus et al. (2016) use clinical features and conventional investigations to facilitate early immunotherapy before antibody status is available. The criteria are satisfied if patients develop four out of six symptom groups within 3 months, together with at least one abnormal investigation (electroencephalography/cerebrospinal fluid) and reasonable exclusion of other disorders. We evaluated the validity of the criteria using a retrospective cohort of paediatric patients with encephalitis. Twenty-nine patients with anti-NMDAR encephalitis and 74 comparison children with encephalitis were included. RESULTS: As expected, the percentage of patients with anti-NMDAR encephalitis who fulfilled the clinical criteria increased over time. During the hospital inpatient admission, most patients (26/29, 90%) with anti-NMDAR encephalitis fulfilled the criteria, significantly more than the comparison group (3/74, 4%) (p<0.001). The median time of fulfilling the criteria in patients with anti-NMDAR encephalitis was 2 weeks from first symptom onset (range 1-6). The sensitivity of the criteria was 90% (95% confidence interval 73-98) and the specificity was 96% (95% confidence interval 89-99). INTERPRETATION: The proposed diagnostic criteria for anti-NMDAR encephalitis have good sensitivity and specificity. Incomplete criteria do not exclude the diagnosis. WHAT THIS PAPER ADDS: The proposed clinical diagnostic criteria for anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis by Graus et al. (2016) have high sensitivity and specificity in paediatric patients. The median time of fulfilling the criteria in patients with anti-NMDAR was 2 weeks from first symptom onset.
AIM: To determine the validity of the proposed clinical diagnostic criteria for anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in paediatric patients. METHOD: The diagnostic criteria for anti-NMDAR encephalitis proposed by Graus et al. (2016) use clinical features and conventional investigations to facilitate early immunotherapy before antibody status is available. The criteria are satisfied if patients develop four out of six symptom groups within 3 months, together with at least one abnormal investigation (electroencephalography/cerebrospinal fluid) and reasonable exclusion of other disorders. We evaluated the validity of the criteria using a retrospective cohort of paediatric patients with encephalitis. Twenty-nine patients with anti-NMDAR encephalitis and 74 comparison children with encephalitis were included. RESULTS: As expected, the percentage of patients with anti-NMDAR encephalitis who fulfilled the clinical criteria increased over time. During the hospital inpatient admission, most patients (26/29, 90%) with anti-NMDAR encephalitis fulfilled the criteria, significantly more than the comparison group (3/74, 4%) (p<0.001). The median time of fulfilling the criteria in patients with anti-NMDAR encephalitis was 2 weeks from first symptom onset (range 1-6). The sensitivity of the criteria was 90% (95% confidence interval 73-98) and the specificity was 96% (95% confidence interval 89-99). INTERPRETATION: The proposed diagnostic criteria for anti-NMDAR encephalitis have good sensitivity and specificity. Incomplete criteria do not exclude the diagnosis. WHAT THIS PAPER ADDS: The proposed clinical diagnostic criteria for anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis by Graus et al. (2016) have high sensitivity and specificity in paediatric patients. The median time of fulfilling the criteria in patients with anti-NMDAR was 2 weeks from first symptom onset.
Authors: Judith N Wagner; Ognian Kalev; Michael Sonnberger; Ingomar Krehan; Tim J von Oertzen Journal: Front Neurol Date: 2018-06-08 Impact factor: 4.003
Authors: Alvin Pumelele Ndondo; Brian Eley; Jo Madeleine Wilmshurst; Angelina Kakooza-Mwesige; Maria Pia Giannoccaro; Hugh J Willison; Pedro M Rodríguez Cruz; Jeannine M Heckmann; Kathleen Bateman; Angela Vincent Journal: Front Immunol Date: 2022-03-09 Impact factor: 7.561
Authors: Tania Cellucci; Heather Van Mater; Francesc Graus; Eyal Muscal; William Gallentine; Marisa S Klein-Gitelman; Susanne M Benseler; Jennifer Frankovich; Mark P Gorman; Keith Van Haren; Josep Dalmau; Russell C Dale Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-01-17
Authors: R Rosello; B Girela-Serrano; M Lim; S Taylor; S Gómez; B Baig Journal: Eur Arch Psychiatry Clin Neurosci Date: 2021-07-17 Impact factor: 5.270